Trial Profile

A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLR 457 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

26 Apr 2019 Planned number of patients changed from 163 to 157.
03 Aug 2018 The overall toxicity profile of patient in dose escalation phase lead the study Investigators and Sponsor to terminate the study, according to results published in the Investigational New Drugs.
03 Aug 2018 Results published in the Investigational New Drugs.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com